(S)-tert-butyl 2-(7-bromo-3,4-dihydrochromeno[4,3-d]imidazol-2-yl)pyrrolidine-1-carboxylate | 1180672-04-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (S)-tert-butyl 2-(7-bromo-3,4-dihydrochromeno[4,3-d]imidazol-2-yl)pyrrolidine-1-carboxylate
• 英文别名: (S)-tert-butyl 2-(7-bromo-1,4-dihydrochromeno[4,3-d]imidazol-2-yl)pyrrolidine-1-carboxylate；tert-butyl (2S)-2-(7-bromo-3,4-dihydrochromeno[3,4-d]imidazol-2-yl)pyrrolidine-1-carboxylate
• CAS: 1180672-04-1
• 化学式: C₁₉H₂₂BrN₃O₃
• 分子量: 420.306
• InChiKey: KJVCPWLWBWWHOX-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  7-溴-4H-色烯-4-酮 在 N-甲基吗啉 、 盐酸羟胺 、 potassium ethoxide 、 ammonium acetate 、 sodium acetate 、 二异丁基氢化铝 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 乙醇 、 正庚烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 、 xylenes 为溶剂， 反应 20.75h， 生成 (S)-tert-butyl 2-(7-bromo-3,4-dihydrochromeno[4,3-d]imidazol-2-yl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] ANTIVIRAL COMPOUNDS
  [FR] COMPOSÉS ANTIVIRAUX

  摘要：

  公开号：

  WO2012068234A3

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Bachand Carol

  公开号：US20090202478A1

  公开（公告）日：2009-08-13

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和用于治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• ANTIVIRAL COMPOUNDS
  申请人：Bacon Elizabeth M.

  公开号：US20140018313A1

  公开（公告）日：2014-01-16

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及抗病毒化合物、含有这种化合物的组合物、包括给予这种化合物的治疗方法，以及用于制备这种化合物的有用过程和中间体。
• Antiviral compounds
  申请人：Bacon Elizabeth M.

  公开号：US09156823B2

  公开（公告）日：2015-10-13

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及抗病毒化合物、含有这种化合物的组合物、包括该化合物的给药治疗方法，以及用于制备这种化合物的过程和中间体。
• Hepatitis C virus inhibitors
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10407445B2

  公开（公告）日：2019-09-10

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物及其药学上可接受的盐、酯或原药： 它们可抑制含 RNA 的病毒，尤其是丙型肝炎病毒（HCV）。因此，本发明的化合物可干扰丙型肝炎病毒的生命周期，也可用作抗病毒药物。本发明进一步涉及包含上述化合物的药物组合物，用于给丙型肝炎病毒感染者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者感染 HCV 的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20160222034A1

  公开（公告）日：2016-08-04

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.